-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Cardiology
- Clinics
- Consumer Products
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Neurology
- OBGYN
- Oncology
- Ophthalmology
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Psychiatry
- Radiology
- Rheumatology
- Risk Manager
- Uncategorized
Category Archives: Psychiatry
Celexa citalopram hydrobromide FDA Drug Safety Communication
Celexa (citalopram hydrobromide) – Drug Safety Communication: Revised Recommendations, Potential Risk of Abnormal Heart Rhythms AUDIENCE: Psychiatry, Cardiology ISSUE: FDA is clarifying dosing and warning recommendations for the antidepressant Celexa (citalopram hydrobromide; also available in generic form). In August 2011, FDA … Continue reading
Posted in Cardiology, FDA 2012, FDA Safety Communication, Psychiatry
Tagged Cardiology, Celexa, Celexa citalopram hydrobromide FDA Drug Safety Communication, citalopram hydrobromide, drug risks, Drug Safety Communication, FDA Drug Safety Communication, FDA notice, FDA warning, Potential Risk of Abnormal Heart Rhythms, Psychiatry, Revised Recommendations, safety label changes
Comments Off
Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants Drug Safety Communication
Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants: Drug Safety Communication – Use During Pregnancy and Potential Risk of Persistent Pulmonary Hypertension of the Newborn Including Celexa (citalopram); Lexapro (escitalopram); Prozac, Sarafem, Symbyax (fluoxetine); Luvox, Luvox CR (fluvoxamine); Paxil, Paxil CR, … Continue reading
Posted in Family Practice, FDA 2011, FDA Notice, OBGYN, Psychiatry
Tagged (SSRI), Antidepressants, Celexa (citalopram), Dietary Supplements, Drug Safety Communication, Family Practice, FDA notice, Lexapro (escitalopram), Luvox, Luvox CR (fluvoxamine), OBGYN, Paxil, Paxil CR, Pexeva (paroxetine), Prozac, Psychiatry, Sarafem, Selective Serotonin Reuptake Inhibitor, Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants, Symbyax (fluoxetine), Viibryd (vilazodone), Zoloft (sertraline)
Comments Off
Saphris asenapine maleate
Saphris (asenapine maleate): Drug Safety Communication: Serious Allergic Reactions AUDIENCE: Psychiatry, Patients ISSUE: FDA notified healthcare professionals and patients that serious allergic reactions have been reported with the use of Saphris (asenapine maleate). The Contraindications, Warnings and Precautions, Adverse Reactions, … Continue reading
Posted in FDA 2011, FDA Label Change, Psychiatry
Tagged asenapine maleate, drug risks, Drug Safety Communication, FDA notice, FDA warning, safety label changes, Saphris
Comments Off
Celexa citalopram hydrobromide
Celexa (citalopram hydrobromide): Drug Safety Communication – Abnormal Heart Rhythms Associated With High Doses AUDIENCE: Psychiatry, Cardiology ISSUE: FDA notified healthcare professionals and patients that the antidepressant Celexa (citalopram hydrobromide) should no longer be used at doses greater than … Continue reading
Posted in FDA 2011, FDA Notice, Psychiatry
Tagged Abnormal Heart Rhythms, Cardiology, Celexa citalopram hydrobromide, dosage, drug risks, FDA notice, FDA warning, Psychiatry, safety label changes
Comments Off
Zyvox (linezolid) Drug Safety Communication
Zyvox (linezolid): Drug Safety Communication – Serious CNS Reactions Possible When Given to Patients Taking Certain Psychiatric Medications AUDIENCE: Infectious Disease, Psychiatry, Family Practice ISSUE: FDA has received reports of serious central nervous system (CNS) reactions when the antibacterial … Continue reading
Posted in Family Practice, FDA 2011, FDA Notice, Infectious Disease, Psychiatry
Tagged Drug Safety Communication, Family Practice, Infectious Disease, linezolid, Psychiatry, Zyvox
Comments Off